6 results about "Neochlorogenic acid" patented technology

The application relates to the field of traditional Chinese medicine quality control, and particularly discloses a quality control method for Shuanghuanglian inhalation solution. The method can simultaneously determine the fingerprint spectrum and ingredient content of the Shuanghuanglian inhalation solution. The fingerprint spectrum detection method disclosed by the application adopts UPLC determination, has 17 characteristic peaks, and attributes 8 characteristic peaks. The contents of neochlorogenic acid, chlorogenic acid, cryptochlorogenic acid, isochlorogenic acid B, isochlorogenic acid A, isochlorogenic acid C and forsythoside are simultaneously determined. Compared with the prior art, the method for determining the fingerprint spectrum and content of the Shuanghuanglian inhalation solution is improved, and the quality of the Shuanghuanglian inhalation solution can be comprehensively monitored conveniently, quickly and accurately.

The present application relates to the technical field of traditional Chinese medicine detection, and provides a genuine three-leafed knot thin-layer identification kit and method, comprising: a chrysophanol control solution, a neochlorogenic acid control solution and a rapid extraction solvent, the rapid extraction solvent contains a low-carbon alcohol, which is used for extracting flavonoid glycoside components in three-leafed knot stem and leaf samples, and the kit is used for identifying the origin of three-leafed knot by detecting the content of chrysophanol and the presence of neochlorogenic acid. The present application uses a chrysophanol and neochlorogenic acid double-index mutual exclusion identification logic, combined with a rapid extraction solvent system without drying, to realize on-site, rapid and accurate identification of the genuineness of three-leafed knot, and effectively solves the problem of origin confusion.

The application discloses application of a medicine composition in preparation of a medicine for treating rheumatoid arthritis (RA), and belongs to the field of RA treating medicines. The medicine composition is composed of swertiamarin (SW) and neochlorogenic acid (NCA) and is screened from two active ingredients in Danteng Yimu Decoction. With the help of animal model and cell model experiments, the action mechanism of the medicine composition in treating RA is explored, the related symptoms and indexes of collagen-induced arthritis (CIA) rats can be effectively improved, joint swelling can be relieved, arthritis inflammation index can be reduced, inflammatory factor release can be inhibited, joint bone quality can be protected, arthritis inflammation infiltration and cartilage destruction can be reduced, and the medicine safety is good. The composition can effectively inhibit the inflammatory factor release and migration ability of rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS). Animal experiments and cell experiments prove that the combination of neochlorogenic acid and swertiamarin (SW+NCA) can be effectively applied to clinical treatment of RA and has a wide application prospect.

This invention belongs to the field of traditional Chinese medicine processing and natural product chemistry, specifically relating to a method for the targeted enrichment of chlorogenic acid components in honeysuckle. The method involves placing honeysuckle powder under constant temperature heating conditions for dry heat treatment. Different dry heat treatment conditions are set according to different target concentrators to achieve the targeted enrichment of various chlorogenic acid components, including neochlorogenic acid, chlorogenic acid, isochlorogenic acid B, and isochlorogenic acid C. This method achieves the targeted and efficient enrichment of effective components during the processing of honeysuckle tablets, and the process is simple, convenient to operate, and easy to scale up for industrial production.

A steviol glycoside solubility enhancer may include a monocaffeoylquinic (MCQ) component that includes at least one compound selected from the group consisting of chlorogenic acid, neochlorogenic acid, cryptochlorogenic acid, and salts thereof; and a dicaffeoylquinic (DCQ) component that includes at least one compound selected from the group consisting of 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, 4,5-dicaffeoylquinic acid, and salts thereof. In one suitable implementation, the MCQ component and the DCQ component together comprise more than 50% (wt), preferably more than 60% (wt), more than 70% (wt), more than 80% (wt), more than 90% (wt), or more than 95% (wt) of the steviol glycoside solubility enhancer.